Multicenter Pharmacokinetic and Pharmacodynamic Study of Pembrolizumab for Non‐small‐Cell Lung Cancer in Patients Aged 75 Years and Older
S Yagishita, Y Yamanaka, T Kurata… - Clinical …, 2024 - Wiley Online Library
Pembrolizumab is a major treatment for recurrent or advanced non‐small‐cell lung cancer
(NSCLC). However, data on its use and pharmacokinetics (PK) in older patients are limited …
(NSCLC). However, data on its use and pharmacokinetics (PK) in older patients are limited …
MO2-4 Multicenter pharmacokinetic study of pembrolizumab for non-small cell lung cancer in older adults aged over 75 years
S Saeki, Y Yamanaka, T Kurata… - Annals of …, 2023 - annalsofoncology.org
Background Pembrolizumab (Pemb) is a key drug for the treatment of advanced or recurrent
non-small cell lung cancer (NSCLC). However, there are limited data on Pemb use in older …
non-small cell lung cancer (NSCLC). However, there are limited data on Pemb use in older …
1482P Multicenter pharmacokinetic study of pembrolizumab for non-small cell lung cancer in elderly adults aged over 75 years
J Sakakibara-Konishi, Y Yamanaka… - Annals of …, 2023 - annalsofoncology.org
Background Pembrolizumab (Pemb) is a key drug for the treatment of advanced or recurrent
non-small cell lung cancer (NSCLC). However, there are limited data on Pemb use in older …
non-small cell lung cancer (NSCLC). However, there are limited data on Pemb use in older …
[HTML][HTML] Treatment rationale and design of the PROLONG study: safety and efficacy of pembrolizumab as first-line therapy for elderly patients with non-small cell lung …
T Masuda, K Fujitaka, N Ishikawa… - Journal of Thoracic …, 2020 - ncbi.nlm.nih.gov
Background Pembrolizumab is recommended as first-line therapy for patients with advanced
non-small cell lung cancer (NSCLC) and a Programmed cell death ligand-1 (PD-L1) tumor …
non-small cell lung cancer (NSCLC) and a Programmed cell death ligand-1 (PD-L1) tumor …
Efficacy and safety of first-line pembrolizumab monotherapy in elderly patients (aged≥ 75 years) with non-small cell lung cancer
H Imai, S Wasamoto, O Yamaguchi, K Suzuki… - Journal of cancer …, 2020 - Springer
Purpose Pembrolizumab is an effective front-line treatment for advanced non-small cell lung
cancer (NSCLC) in patients expressing high levels of programmed death-ligand 1 (PD-L1) …
cancer (NSCLC) in patients expressing high levels of programmed death-ligand 1 (PD-L1) …
Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1–positive advanced non–small-cell lung cancer: Pooled analysis from the KEYNOTE …
K Nosaki, H Saka, Y Hosomi, P Baas, G de Castro Jr… - Lung Cancer, 2019 - Elsevier
Objectives Most lung cancer diagnoses occur in elderly patients, who are underrepresented
in clinical trials. We present a pooled analysis of safety and efficacy in elderly patients (≥ 75 …
in clinical trials. We present a pooled analysis of safety and efficacy in elderly patients (≥ 75 …
Phase 2 study of first‐line pembrolizumab monotherapy in elderly patients with non‐small‐cell lung cancer expressing high PD‐L1
T Masuda, K Fujitaka, T Suzuki, K Hamai… - Thoracic …, 2022 - Wiley Online Library
Background Pembrolizumab is the recommended first‐line therapy for patients with
advanced non‐small‐cell lung cancer (NSCLC) and a programmed death ligand‐1 (PD‐L1) …
advanced non‐small‐cell lung cancer (NSCLC) and a programmed death ligand‐1 (PD‐L1) …
Clinical impact of pembrolizumab combined with chemotherapy in elderly patients with advanced non-small-cell lung cancer
K Morimoto, T Yamada, T Yokoi, T Kijima, Y Goto… - Lung Cancer, 2021 - Elsevier
Objectives Combination therapy of immune checkpoint inhibitors and chemotherapy is
considered to be one of the standard treatment options for patients with advanced non-small …
considered to be one of the standard treatment options for patients with advanced non-small …
Pembrolizumab plus chemotherapy versus chemotherapy monotherapy as a first-line treatment in elderly patients (≥ 75 years old) with non-small-cell lung cancer
Z Yang, Y Chen, Y Wang, M Hu, F Qian… - Frontiers in …, 2022 - frontiersin.org
Objective Several trials have shown that pembrolizumab plus chemotherapy was more
effective in patients with advanced non-small-cell lung cancer (NSCLC) than chemotherapy …
effective in patients with advanced non-small-cell lung cancer (NSCLC) than chemotherapy …
94P Efficacy of first-line pembrolizumab in elderly patients with advanced non-small cell lung cancer with high PD-L1 expression
F Markovic, MK Jovanovic, U Janzic - ESMO Open, 2024 - esmoopen.com
Background Pembrolizumab monotherapy is the standard of care for first-line treatment of
advanced non-oncogene driven non-small cell lung cancer (NSCLC) patients with high …
advanced non-oncogene driven non-small cell lung cancer (NSCLC) patients with high …
相关搜索
- small cell lung cancer
- lung cancer pd l1
- lung cancer elderly patients
- lung cancer pembrolizumab monotherapy
- lung cancer clinical impact
- safety and efficacy elderly patients
- safety and efficacy treatment rationale
- treatment rationale elderly patients
- pd l1 elderly patients
- pd l1 pembrolizumab monotherapy
- pembrolizumab monotherapy elderly patients
- efficacy of pembrolizumab elderly patients
- clinical impact elderly patients